Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acurx Pharmaceuticals, LLC*

0.4573
-0.1947-29.86%
Post-market: 0.46980.0125+2.73%19:52 EST
Volume:1.18M
Turnover:548.26K
Market Cap:8.91M
PE:-0.43
High:0.5000
Open:0.4605
Low:0.4500
Close:0.6520
Loading ...

Dow Dips Over 250 Points; Genesco Shares Plunge After Q4 Results

Benzinga
·
08 Mar

Acurx Pharmaceuticals Launches $1.1 Million Registered Direct Offering; Shares Fall

MT Newswires Live
·
07 Mar

BRIEF-Acurx Pharmaceuticals Announces $1.1 Million Registered Direct Offering

Reuters
·
07 Mar

Acurx to sell 2.745M shares at 40c in registered direct offering

TIPRANKS
·
07 Mar

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

THOMSON REUTERS
·
07 Mar

Acurx Announces Publication of Nonclinical in Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects From Other Anti-Cdi Antibiotics

THOMSON REUTERS
·
03 Mar

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

CNW Group
·
03 Mar

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

PR Newswire
·
28 Feb

Acurx Announces Publication of Positive Results From an in-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of Cdi

THOMSON REUTERS
·
24 Feb

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

CNW Group
·
24 Feb

Acurx new patent granted by JPO related to DNA Polymerase IIIC Inhibitors

TIPRANKS
·
19 Feb

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

PR Newswire
·
19 Feb

Acurx Pharmaceuticals Says Selling Shareholders May Sell 2.6 Million Shares

MT Newswires Live
·
01 Feb

H.C. Wainwright Reaffirms Their Buy Rating on Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
13 Jan

Acurx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Jan

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
08 Jan